CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

The absolute and relative HIV-attributable cancer burden varies globally. These data can inform region-specific planning and evaluation of HIV control, as well as cancer-specific interventions such as ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Some HIV drugs have weird psychedelic side effects, but these can be augmented with medical cannabis.

Malawi is bolstering efforts to protect its phenomenal progress in the fight against HIV as sudden donor funding cuts, especially from the United States (US), threaten vital services. Like many ...